William Blair Investment Management LLC grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 2.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 306,107 shares of the company’s stock after purchasing an additional 7,953 shares during the period. William Blair Investment Management LLC’s holdings in IDEXX Laboratories were worth $159,846,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Aurora Investment Managers LLC. acquired a new stake in IDEXX Laboratories during the 2nd quarter worth $2,442,000. National Pension Service grew its stake in IDEXX Laboratories by 5.6% in the second quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after acquiring an additional 6,885 shares during the period. Howard Capital Management LLC acquired a new position in IDEXX Laboratories in the third quarter valued at about $1,249,000. NewEdge Advisors LLC increased its holdings in shares of IDEXX Laboratories by 60.9% in the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock worth $8,552,000 after acquiring an additional 5,761 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in shares of IDEXX Laboratories by 4.9% in the second quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock worth $11,988,000 after acquiring an additional 1,074 shares in the last quarter. 87.84% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the company. UBS Group raised their price target on IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. Barclays decreased their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Morgan Stanley increased their target price on IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. KeyCorp started coverage on shares of IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating on the stock. Finally, The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They issued a “buy” rating and a $740.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $717.27.
Check Out Our Latest Report on IDEXX Laboratories
Insider Activity at IDEXX Laboratories
In other news, EVP Sharon Underberg sold 8,906 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total transaction of $6,132,582.54. Following the completion of the transaction, the executive vice president directly owned 7,169 shares of the company’s stock, valued at $4,936,501.71. This represents a 55.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Daniel Junius sold 1,200 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $704.07, for a total value of $844,884.00. Following the transaction, the director owned 2,361 shares of the company’s stock, valued at approximately $1,662,309.27. The trade was a 33.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 41,428 shares of company stock valued at $28,567,934 over the last ninety days. Company insiders own 0.79% of the company’s stock.
IDEXX Laboratories Price Performance
Shares of NASDAQ IDXX opened at $704.23 on Monday. The firm has a market cap of $55.48 billion, a PE ratio of 47.49 and a beta of 1.55. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98. The company has a fifty day moving average price of $562.41 and a 200 day moving average price of $573.52.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter in the prior year, the company earned $3.22 EPS. The company’s revenue was up 9.9% on a year-over-year basis. Research analysts predict that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.
About IDEXX Laboratories
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
